Absence of TTF-1 Immunoreactivity Can Predict EGFR Wild-Type in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Bosdet, I. [1 ]
Young, S. S. [1 ]
Ali, R. H. [1 ]
McNeil, B. K. [1 ]
Wong, C. [1 ]
Garbutt, K. [1 ]
Karsan, A. [1 ]
Ionescu, D. N. [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
LABORATORY INVESTIGATION | 2012年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1974
引用
收藏
页码：474A / 474A
页数：1
相关论文
共 50 条
  • [41] Fascin immunoreactivity correlates with tumor grade in non-small cell lung cancer (NSCLC).
    del Rosario, A
    Goncharuk, VN
    Tran, TA
    Sheehan, CE
    Ross, JS
    LABORATORY INVESTIGATION, 2001, 81 (01) : 218A - 218A
  • [42] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer Cancer
    Minemura H.
    Yokouchi H.
    Azuma K.
    Hirai K.-I.
    Sekine S.
    Oshima K.
    Kanazawa K.
    Tanino Y.
    Inokoshi Y.
    Ishii T.
    Katsuura Y.
    Oishi A.
    Ishida T.
    Munakata M.
    BMC Research Notes, 8 (1)
  • [43] P53 is potential predictive biomarker for combination therapy of epidermal growth factor receptor (EGFR) and MET inhibitors in non-small cell lung cancer (NSCLC) with wild-type EGFR
    Hong, Yun Kyoung
    Kim, Sun Mi
    Sung, Ji Hee
    Duong, Hong-Quan
    Kim, Joo-Hang
    Cho, Byoung Chul
    CANCER RESEARCH, 2012, 72
  • [44] Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC)
    Kim, Hye Ryun
    Saavedra, Omar
    Cervantes, Andres
    Lugowska, Iwona A.
    Oberoi, Arjun
    El-Khoueiry, Anthony B.
    Thomas, Jacob Stephen
    Rogowski, Wojciech
    Lopez, Juanita Suzanne
    Shim, Byoung Yong
    Christenson, Eric
    Boni, Valentina
    Garassino, Marina Chiara
    Yarza, Ramon
    Gaertner, Ulrike
    Lutkewitz, Sarah
    Shuetz, Daniel
    Pietzko, Kerstin
    Emig, Michael
    Espinosa, Daniela Morales
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
    Takeuchi, Akira
    Oguri, Tetsuya
    Yamashita, Yoriko
    Sone, Kazuki
    Fukuda, Satoshi
    Takakuwa, Osamu
    Uemura, Takehiro
    Maeno, Ken
    Fukumitsu, Kensuke
    Kanemitsu, Yoshihiro
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Ito, Yutaka
    Niimi, Akio
    ANTICANCER RESEARCH, 2018, 38 (09) : 5489 - 5495
  • [46] Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study
    Paz-Arez, Luis
    Serwatowski, Piotr
    Szczesna, Aleksandra
    Von Pawel, Joachim
    Toschi, Luca
    Tibor, Csoszi
    Morabito, Alessandro
    Zhang, Ling
    Shuster, Dale
    Chen, Shuquan
    Copigneaux, Catherine
    Akerley, Wallace
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1214 - S1215
  • [47] Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer
    Zheng, Zhi S.
    Xia, Bing
    Xie, Rui F.
    Li, Xia D.
    Zhu, Jue
    Wu, Shi X.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S548
  • [48] Can the epidermal growth factor receptor (EGFR) expression predict survival in surgically resected non-small cell lung cancer (NSCLC) patients?
    Gately, Kathy A.
    Coate, Linda
    Cuffe, Sinead
    Pidgeon, Graham
    O'Byrne, Kenneth
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S906 - S906
  • [49] Amplification of wild-type RET and clinical response to selpercatinib for non-small-cell lung cancer (NSCLC)
    Gandhi, Malini Marion
    Ricciuti, Biagio
    Gildenberg, Melissa
    Singh, Ankit
    Li, Yvonne Y.
    Gagne, Andreanne
    Wang, Xinan
    Fitzgerald, Kelly
    Aizer, Ayal
    Nishino, Mizuki
    Alessi, Joao Victor Machado
    Pecci, Federica
    Di Federico, Alessandro
    Fisch, Adam
    Nardi, Valentina
    Sholl, Lynette M.
    Awad, Mark M.
    Rotow, Julia K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer
    Kim, Boyeon
    Park, Young Soo
    Sung, Jae Sook
    Lee, Jong Won
    Lee, Saet Byeol
    Kim, Yeul Hong
    CANCER MEDICINE, 2021, 10 (01): : 372 - 385
12345